[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20001631L - 2-metyl-tieno-benzodiazepin formulering - Google Patents

2-metyl-tieno-benzodiazepin formulering

Info

Publication number
NO20001631L
NO20001631L NO20001631A NO20001631A NO20001631L NO 20001631 L NO20001631 L NO 20001631L NO 20001631 A NO20001631 A NO 20001631A NO 20001631 A NO20001631 A NO 20001631A NO 20001631 L NO20001631 L NO 20001631L
Authority
NO
Norway
Prior art keywords
thieno
methyl
benzodiazepine formulation
benzodiazepine
formulation
Prior art date
Application number
NO20001631A
Other languages
English (en)
Other versions
NO20001631D0 (no
Inventor
Douglas James Allen
Kurt Douglas Dekemper
Thomas Harry Ferguson
Stuart James Garvin
Linda Cameron Murray
Norman Dale Brooks
Charles A Bunnell
Barry A Hendriksen
Snehlata Singh Mascarenhas
Sharon Louise Shinkle
Manuel Vicente Sanchez-Felix
David Edward Tupper
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20001631D0 publication Critical patent/NO20001631D0/no
Publication of NO20001631L publication Critical patent/NO20001631L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
NO20001631A 1997-09-30 2000-03-29 2-metyl-tieno-benzodiazepin formulering NO20001631L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6049397P 1997-09-30 1997-09-30
PCT/US1998/020426 WO1999016313A1 (en) 1997-09-30 1998-09-30 2-methyl-thieno-benzodiazepine formulation

Publications (2)

Publication Number Publication Date
NO20001631D0 NO20001631D0 (no) 2000-03-29
NO20001631L true NO20001631L (no) 2000-05-30

Family

ID=22029843

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001631A NO20001631L (no) 1997-09-30 2000-03-29 2-metyl-tieno-benzodiazepin formulering

Country Status (20)

Country Link
US (1) US6169084B1 (no)
EP (1) EP1018880A4 (no)
JP (2) JP4503826B2 (no)
KR (1) KR100537713B1 (no)
CN (1) CN1239158C (no)
AU (1) AU752552C (no)
BR (1) BR9813228A (no)
CA (1) CA2304568C (no)
CZ (1) CZ300725B6 (no)
EA (1) EA002825B1 (no)
HR (1) HRP20000181B1 (no)
HU (1) HUP0004534A3 (no)
ID (1) ID25533A (no)
IL (2) IL135295A0 (no)
NO (1) NO20001631L (no)
NZ (1) NZ503641A (no)
PL (1) PL339864A1 (no)
TR (1) TR200000812T2 (no)
UA (1) UA73715C2 (no)
WO (1) WO1999016313A1 (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617321B2 (en) * 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
ES2221376T3 (es) * 1998-09-30 2004-12-16 ELI LILLY & COMPANY Formulacion de 2-metil-tieno-benzodiazepina.
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US20040067936A1 (en) * 2000-08-31 2004-04-08 Reguri Buchi Reddy Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
US6988887B2 (en) * 2002-02-18 2006-01-24 3M Innovative Properties Company Orthodontic separators
WO2004058773A1 (en) * 2002-12-24 2004-07-15 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
HU226410B1 (en) * 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
WO2005070938A1 (en) 2004-01-27 2005-08-04 Synthon B.V. Stable salts of olanzapine
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
US7910577B2 (en) * 2004-11-16 2011-03-22 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
US20090155331A1 (en) * 2005-11-16 2009-06-18 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
CA2593471A1 (en) * 2004-12-10 2006-07-06 University Of Connecticut Shape memory polymer orthodontic appliances, and methods of making and using the same
PT1838716E (pt) * 2005-01-05 2011-07-15 Lilly Co Eli Di-hidrato de pamoato de olanzapina
CZ2006697A3 (cs) * 2006-11-07 2008-05-21 Zentiva, A. S. Kompozice depotních olanzapinových injekcních systému
US9161943B2 (en) 2007-12-31 2015-10-20 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
EP2440162A1 (en) * 2009-06-08 2012-04-18 Boston Scientific Scimed, Inc. Crosslinked bioabsorbable medical devices
CA2766291C (en) 2009-06-24 2016-06-21 Msd Oss B.V. Injectable formulations containing asenapine and method of treatment using same
WO2011091142A2 (en) 2010-01-20 2011-07-28 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of olanzapine pamoate
JP5222917B2 (ja) * 2010-09-21 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
CN107625728A (zh) 2010-10-18 2018-01-26 大日本住友制药株式会社 注射用缓释制剂
LT3156056T (lt) 2011-03-18 2024-02-26 Alkermes Pharma Ireland Limited Farmacinės kompozicijos, apimančios sorbitano esterius
WO2013078608A1 (en) * 2011-11-29 2013-06-06 Ziqiang Gu Donepezil pamoate and methods of making and using the same
CA2858787C (en) 2011-12-15 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of tertiary amine compounds
US10004807B2 (en) 2012-03-19 2018-06-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
JP6219918B2 (ja) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
WO2013142205A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
JP6042153B2 (ja) * 2012-09-26 2016-12-14 株式会社トクヤマ オランザピンの製造方法
US20160175313A1 (en) 2013-08-06 2016-06-23 Dongkook Pharmaceutical Co., Ltd., Entecavir microspheres and pharmaceutical composition for parenteral administration containing same
US9883922B2 (en) 2013-11-29 2018-02-06 Dentsply Sirona Inc. Dental wedge
US9452131B2 (en) 2014-03-20 2016-09-27 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
ITUB20153652A1 (it) * 2015-09-16 2017-03-16 Fatro Spa Microsfere contenenti lattoni macrociclici antielminitici
CN116942677A (zh) * 2015-09-21 2023-10-27 梯瓦制药国际有限责任公司 缓释奥氮平制剂
AU2018238136A1 (en) 2017-03-20 2019-11-07 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
WO2019136308A1 (en) 2018-01-05 2019-07-11 Impel Neuropharma, Inc. Intranasal delivery of olanzapine by precision olfactory device
JP7384812B2 (ja) 2018-03-05 2023-11-21 アルカームス ファーマ アイルランド リミテッド アリピプラゾール投与戦略
CN108969478A (zh) * 2018-08-29 2018-12-11 江南大学 一种美金刚难溶盐缓释注射剂及其制备方法
CA3177848A1 (en) * 2020-05-05 2021-11-11 Guochuan Emil Tsai Salts of neuroceuticals and uses thereof
CN112569191A (zh) * 2020-10-16 2021-03-30 长春斯菲尔生物科技有限公司 一种奥氮平双羟萘酸盐缓释微粒制剂喷雾制备方法
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
IL314293A (en) * 2022-01-20 2024-09-01 Teva Pharmaceuticals Int Gmbh Olanzapine, its compounds and methods of using it
TW202430220A (zh) * 2022-11-16 2024-08-01 逸達生物科技股份有限公司 用於囊泡單胺轉運蛋白2 (vmat2) 抑制劑之補給型組合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3324192A1 (de) * 1983-07-05 1985-01-17 Troponwerke Gmbh & Co Kg Depot-antiphlogistika
US4816247A (en) * 1985-09-11 1989-03-28 American Cyanamid Company Emulsion compositions for administration of sparingly water soluble ionizable hydrophobic drugs
US4784845A (en) * 1985-09-16 1988-11-15 American Cyanamid Company Emulsion compostions for the parenteral administration of sparingly water soluble ionizable hydrophobic drugs
JPH01284333A (ja) * 1988-05-11 1989-11-15 T Hasegawa Co Ltd 乳化液組成物
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
CA2178592C (en) 1993-12-09 2009-07-28 Jurgen Engel Long-acting injection suspensions and a process for their preparation
JP3701693B2 (ja) * 1993-12-28 2005-10-05 日本製薬株式会社 鎮痛薬含有注射用徐放性脂肪乳剤
US6333021B1 (en) * 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
US5776928A (en) * 1995-04-21 1998-07-07 Eli Lilly And Company Method for treating dyskinesias with olanzapine
EP0831835B1 (en) * 1995-06-01 2002-10-30 Eli Lilly And Company Treating anorexia
US5602897A (en) * 1995-06-29 1997-02-11 Picker International, Inc. High-voltage power supply for x-ray tubes
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
JPH09157159A (ja) * 1995-12-11 1997-06-17 Lion Corp カロチノイド含有組成物

Also Published As

Publication number Publication date
AU752552C (en) 2003-09-11
AU752552B2 (en) 2002-09-19
JP2010138208A (ja) 2010-06-24
KR100537713B1 (ko) 2005-12-20
AU9591498A (en) 1999-04-23
HUP0004534A3 (en) 2002-10-28
CA2304568A1 (en) 1999-04-08
UA73715C2 (en) 2005-09-15
NO20001631D0 (no) 2000-03-29
CN1271251A (zh) 2000-10-25
HUP0004534A2 (hu) 2001-05-28
EP1018880A1 (en) 2000-07-19
TR200000812T2 (tr) 2001-07-23
EA200000381A1 (ru) 2000-10-30
IL135295A0 (en) 2001-05-20
CZ20001162A3 (cs) 2000-09-13
US6169084B1 (en) 2001-01-02
HRP20000181B1 (en) 2006-07-31
BR9813228A (pt) 2000-08-29
EP1018880A4 (en) 2006-06-14
CZ300725B6 (cs) 2009-07-29
EA002825B1 (ru) 2002-10-31
ID25533A (id) 2000-10-12
KR20010030774A (ko) 2001-04-16
HRP20000181A2 (en) 2000-12-31
CA2304568C (en) 2008-08-12
JP4503826B2 (ja) 2010-07-14
NZ503641A (en) 2002-09-27
WO1999016313A1 (en) 1999-04-08
CN1239158C (zh) 2006-02-01
IL135295A (en) 2006-10-31
PL339864A1 (en) 2001-01-15
JP2001517685A (ja) 2001-10-09

Similar Documents

Publication Publication Date Title
NO20001631L (no) 2-metyl-tieno-benzodiazepin formulering
DE19810476B4 (de) Laryngomaske
MA24473A1 (fr) Formulations
ATA93198A (de) Fluoxetinpellets
ID28698A (id) Formulasi antiparasit
ID29635A (id) Formulasi mikrokapsul
ID27655A (id) Formulasi mikrokapsul
DE59802506D1 (de) Weichspülmittelzusammemsetzung
DE59801498D1 (de) Dioxacycloalkan-8-one
DE59710388D1 (de) Mikropolarimeter
NO20002555D0 (no) Skjøt
ATA111897A (de) Kimme
ATE236897T1 (de) 3-benzylpiperidine
ATA112597A (de) Snowboard - bindung
ID23663A (id) Persiapan kaprolaktam
ATA86797A (de) Verschleissschuh
DE59800820D1 (de) Stiellose kniegelenkendoprothese
ATA46498A (de) Kunststoffgleitbahn
BR9701194A (pt) Hidrociclo
SE9800766D0 (sv) Formulation
SE9800170D0 (sv) Formulation
SE9803106D0 (sv) Novel formulation
BR9700328A (pt) Conjunto tampa-recipiente
BR7702215U (pt) Conjunto pia-fogão
ATE421585T1 (de) Motlinhomologe

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application